A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

NCT00216632 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Psychotic Disorders

Interventions

DRUG: risperidone

Sponsor

Janssen Pharmaceutica N.V., Belgium